<br />
In this episode we talk to <a href="https://twitter.com/ToxInNewEngland" target="_blank" rel="noopener noreferrer">Ed Boyer</a> about Kratom, pharmacology, legal status, and discuss recent reports of adverse effects.<br />
<br />
* Boyer et al <a href="https://www.ncbi.nlm.nih.gov/pubmed/18482427" target="_blank" rel="noopener noreferrer">Self-treatment of opioid withdrawal using kratom (Mitragynia speciosa korth)</a><br />
* <a href="https://www.fda.gov/NewsEvents/PublicHealthFocus/ucm584952.htm" target="_blank" rel="noopener noreferrer">FDA response to Kratom</a><br />
* <a href="https://en.wikipedia.org/wiki/Bradford_Hill_criteria" target="_blank" rel="noopener noreferrer">Bradford Hill Criteria</a><br />
<br />
Take Home Points:<br />
<br />
* Kratom is an opioid agonist<br />
* Patients should not mix Kratom with other substances<br />
* Patients at risk of seizures should not use Kratom<br />
* Kratom will not show up on a typical urine drug screen<br />
<br />

ToxNow

ToxNow

Episode 41 Kratom: Friend or Foe

APR 8, 201822 MIN
ToxNow

Episode 41 Kratom: Friend or Foe

APR 8, 201822 MIN

Description

In this episode we talk to Ed Boyer about Kratom, pharmacology, legal status, and discuss recent reports of adverse effects.

Take Home Points:

  • Kratom is an opioid agonist
  • Patients should not mix Kratom with other substances
  • Patients at risk of seizures should not use Kratom
  • Kratom will not show up on a typical urine drug screen

The post Episode 41 Kratom: Friend or Foe first appeared on ToxNow.